title: Efficacy of anticholinergics for chronic prostatitis/chronic pelvic pain syndrome in young and middle-aged patients: a single-blinded, prospective, multi-center study.
abstract: OBJECTIVE
  Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) exhibits variable lower urinary tract symptoms (LUTS). The aim of this study was to evaluate the incidence of LUTS and the efficacy of an anticholinergic agent in young and middle-aged CP/CPPS patients.
  
  
  METHODS
  Ninety-six men with CP/CPPS were randomly assigned in a single-blind fashion and received either ciprofloxacin (group 1, 49 patients) or ciprofloxacin and solifenacin (5 mg/day; group 2, 47 patients) for 8 weeks. The National Institutes of Health chronic prostatitis symptom index (NIH-CPSI), the International Prostate Symptom Score (IPSS), and the International Index of Erectile Function-5 (IIEF-5) were used to grade the patients' symptoms and the quality of life impact at the start of the study, and at 4 and 8 weeks from the initiation of the study.
  
  
  RESULTS
  There was no significant difference between groups 1 and 2 with respect to age, duration of disease, or sub-domains of the IPSS, NIH-CPSI, or IIEF-5 at baseline. Of these patients, 67.4% had LUTS. Statistically significant differences were determined via the NIH-CPSI for total score and the pain and urinary domain scores. Statistically significant differences were determined via the IPSS for total score and the storage domain score. The total score of the IIEF-5 increased, but the change was not significant. There was no statistically significant difference in residual urine.
  
  
  CONCLUSIONS
  Many CP/CPPS patients had LUTS. Solifenacin in CP/CPPS demonstrated improvements in the NIH-CPSI and the IPSS total score and storage score. Storage factors significantly improved via the NIH-CPSI and IPSS assessments in the solifenacin treatment group.
authors.affiliation: Department of Urology, Soonchunhyang University College of Medicine, Cheonan, Korea.
authors.forename: Doo Sang
authors.initials: DS
authors.lastname: Kim
authors.forename: Yoon Soo
authors.initials: YS
authors.lastname: Kyung
authors.forename: Seung Hyo
authors.initials: SH
authors.lastname: Woo
authors.forename: Young Seop
authors.initials: YS
authors.lastname: Chang
authors.forename: Hyung-Jee
authors.initials: HJ
authors.lastname: Kim
references.citation: Eur Urol. 2004 Dec;46(6):681-9
references.pmid: 15548433
references.citation: J Urol. 1998 Apr;159(4):1224-8
references.pmid: 9507840
references.citation: Urology. 2000 Dec 20;56(6):951-5
references.pmid: 11113739
references.citation: Urology. 2002 Dec;60(6 Suppl):14-8; discussion 18-9
references.pmid: 12521581
references.citation: JAMA. 1999 Jul 21;282(3):236-7
references.pmid: 10422990
references.citation: Ann Intern Med. 2000 Sep 5;133(5):367-81
references.pmid: 10979882
references.citation: Andrologia. 2003 Oct;35(5):252-7
references.pmid: 14535850
references.citation: J Urol. 2002 Aug;168(2):593-8
references.pmid: 12131316
references.citation: Ther Adv Urol. 2009 Oct;1(4):209-21
references.pmid: 21789068
references.citation: Eur Urol. 2003 Dec;44(6):637-49
references.pmid: 14644114
references.citation: J Eur Acad Dermatol Venereol. 2002 May;16(3):253-6
references.pmid: 12195565
references.citation: BJU Int. 2004 Sep;94(4):568-70
references.pmid: 15329114
references.citation: J Urol. 2002 Mar;167(3):1363-6
references.pmid: 11832733